Literature DB >> 27889361

Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.

Timothy R Aksamit1, Anne E O'Donnell2, Alan Barker3, Kenneth N Olivier4, Kevin L Winthrop5, M Leigh Anne Daniels6, Margaret Johnson7, Edward Eden8, David Griffith9, Michael Knowles6, Mark Metersky10, Matthias Salathe11, Byron Thomashow12, Gregory Tino13, Gerard Turino14, Betsy Carretta15, Charles L Daley16.   

Abstract

OBJECTIVES: We sought to describe the characteristics of adult patients with bronchiectasis enrolled in the US Bronchiectasis Research Registry (BRR).
METHODS: The BRR is a database of patients with non-cystic-fibrosis bronchiectasis (NCFB) enrolled at 13 sites in the United States. Baseline demographic, spirometric, imaging, microbiological, and therapeutic data were entered into a central Internet-based database. Patients were subsequently analyzed by the presence of NTM.
RESULTS: We enrolled 1,826 patients between 2008 and 2014. Patients were predominantly women (79%), white (89%), and never smokers (60%), with a mean age of 64 ± 14 years. Sixty-three percent of the patients had a history of NTM disease or NTM isolated at baseline evaluation for entry into the BRR. Patients with NTM were older, predominantly women, and had bronchiectasis diagnosed at a later age than those without NTM. Gastroesophageal reflux disease (GERD) was more common in those with NTM, whereas asthma, primary immunodeficiency, and primary ciliary dyskinesia were more common in those without NTM. Fifty-one percent of patients had spirometric evidence of airflow obstruction. Patients with NTM were more likely to have diffusely dilated airways and tree-in-bud abnormalities. Pseudomonas and Staphylococcus aureus isolates were cultured less commonly in patients with NTM. Bronchial hygiene measures were used more often in those with NTM, whereas antibiotics used for exacerbations, rotating oral antibiotics, steroid use, and inhaled bronchodilators were more commonly used in those without NTM.
CONCLUSIONS: Adult patients with bronchiectasis enrolled in the US BRR are described, with differences noted in demographic, radiographic, microbiological, and treatment variables based on stratification of the presence of NTM.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Pseudomonas; airways; bronchiectasis; nontuberculous mycobacteria; registry

Mesh:

Year:  2016        PMID: 27889361      PMCID: PMC6026266          DOI: 10.1016/j.chest.2016.10.055

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

Review 1.  British Thoracic Society guideline for non-CF bronchiectasis.

Authors:  M C Pasteur; D Bilton; A T Hill
Journal:  Thorax       Date:  2010-07       Impact factor: 9.139

2.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007.

Authors:  Amy E Seitz; Kenneth N Olivier; Jennifer Adjemian; Steven M Holland; D Rebecca Prevots
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

Review 3.  The initial evaluation of adults with bronchiectasis.

Authors:  Mark L Metersky
Journal:  Clin Chest Med       Date:  2012-04-20       Impact factor: 2.878

4.  Aetiology in adult patients with bronchiectasis.

Authors:  A Shoemark; L Ozerovitch; R Wilson
Journal:  Respir Med       Date:  2007-01-12       Impact factor: 3.415

5.  Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease.

Authors:  Won-Jung Koh; Jun Haeng Lee; Yong Soo Kwon; Kyung Soo Lee; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O Jung Kwon
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

6.  Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa.

Authors:  S A Evans; S M Turner; B J Bosch; C C Hardy; M A Woodhead
Journal:  Eur Respir J       Date:  1996-08       Impact factor: 16.671

7.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.

Authors:  Richard D Kim; David E Greenberg; Mary E Ehrmantraut; Shireen V Guide; Li Ding; Yvonne Shea; Margaret R Brown; Milica Chernick; Wendy K Steagall; Connie G Glasgow; JingPing Lin; Clara Jolley; Lynn Sorbara; Mark Raffeld; Suvimol Hill; Nilo Avila; Vandana Sachdev; Lisa A Barnhart; Victoria L Anderson; Reginald Claypool; Dianne M Hilligoss; Mary Garofalo; Alan Fitzgerald; Sandra Anaya-O'Brien; Dirk Darnell; Rosamma DeCastro; Heather M Menning; Stacy M Ricklefs; Stephen F Porcella; Kenneth N Olivier; Joel Moss; Steven M Holland
Journal:  Am J Respir Crit Care Med       Date:  2008-08-14       Impact factor: 21.405

Review 8.  Non-cystic fibrosis bronchiectasis.

Authors:  Pamela J McShane; Edward T Naureckas; Gregory Tino; Mary E Strek
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

9.  Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease.

Authors:  Rachel M Thomson; John G Armstrong; David F Looke
Journal:  Chest       Date:  2007-04       Impact factor: 9.410

10.  Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.

Authors:  Sara Lonni; James D Chalmers; Pieter C Goeminne; Melissa J McDonnell; Katerina Dimakou; Anthony De Soyza; Eva Polverino; Charlotte Van de Kerkhove; Robert Rutherford; John Davison; Edmundo Rosales; Alberto Pesci; Marcos I Restrepo; Antoni Torres; Stefano Aliberti
Journal:  Ann Am Thorac Soc       Date:  2015-12
View more
  80 in total

Review 1.  Medical management of bronchiectasis.

Authors:  Anne E O'Donnell
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 2.  Surgical management of non-cystic fibrosis bronchiectasis.

Authors:  Miyako Hiramatsu; Yuji Shiraishi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 3.  Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity.

Authors:  Patrick A Flume; James D Chalmers; Kenneth N Olivier
Journal:  Lancet       Date:  2018-09-08       Impact factor: 79.321

Review 4.  Macrophage Signaling Pathways in Pulmonary Nontuberculous Mycobacteria Infections.

Authors:  Zohra Prasla; Roy L Sutliff; Ruxana T Sadikot
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

5.  Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.

Authors:  Emily Henkle; Timothy R Aksamit; Alan F Barker; Jeffrey R Curtis; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Edward Eden; Kevin Fennelly; David E Griffith; Margaret Johnson; Michael R Knowles; Amy Leitman; Philip Leitman; Elisha Malanga; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Delia Prieto; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Susan Wisclenny; Kevin L Winthrop
Journal:  Chest       Date:  2017-05-05       Impact factor: 9.410

6.  Rare Disease Registries: Steps Forward.

Authors:  Charlie Strange
Journal:  Chronic Obstr Pulm Dis       Date:  2019-04

7.  Diminished Susceptibility of African-Americans to Non-tuberculous Mycobacterial Disease.

Authors:  Jerome M Reich; Jong S Kim
Journal:  Lung       Date:  2017-11-13       Impact factor: 2.584

Review 8.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

9.  Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells.

Authors:  Britton C Goodale; Erica J Rayack; Bruce A Stanton
Journal:  Toxicol Appl Pharmacol       Date:  2017-06-15       Impact factor: 4.219

10.  Clinical Determinants of Incremental Shuttle Walk Test in Adults with Bronchiectasis.

Authors:  Sulenur Yildiz; Deniz Inal-Ince; Ebru Calik-Kutukcu; Naciye Vardar-Yagli; Melda Saglam; Hulya Arikan; Lutfi Coplu
Journal:  Lung       Date:  2018-02-12       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.